Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Barrett Esophagus 1

Interventions

Gemcitabine 7Cisplatin 6durvalumab 5pembrolizumab 4gemcitabine-oxaliplatin regimen 3S 1 (combination) 3Carboplatin 3Trastuzumab 2Paclitaxel 2Capecitabine 2tucatinib 1tremelimumab 1merestinib 1irinotecan sucrosofate 1envafolimab 1Tegafur 1Ramucirumab 1Radiation 1Psilocybin 1Poly(ADP-ribose) Polymerase Inhibitors 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Leucovorin 1Itraconazole 1Immune Checkpoint Inhibitors 1High-Throughput Nucleotide Sequencing 1Fulvestrant 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Biliary Tract Neoplasms × Itraconazole × Clear all
NCT06084481 2026-01-20

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

AbbVie

Phase 1 Active not recruiting
302 enrolled
BreastGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡